Oligometastatic disease
Cancer that has spread to only a few places, which may still be curable by treating each spot.
Overview
Oligometastatic disease is cancer that has spread to only a few sites, usually no more than three to five metastases, and may still be curable if each spot is treated. The SABR-COMET trial supported metastasis-directed SBRT / SABR (stereotactic radiotherapy), and the ESTRO/EORTC classification distinguishes synchronous, oligorecurrent and oligoprogressive disease, the last covered by the related term Oligoprogression. PSMA PET has expanded detection of this state in Prostate cancer, and the term is also referenced by the Renal cell carcinoma entry and the bottleneck on metastasis biology. Ideas building on it include PSMA-PET-guided metastasis-directed therapy as a curative strategy and a test to tell true oligometastatic disease from hidden widespread spread.
- Detector ring
- PSMA ligand
- 511 keV photon pair
Showing the technology this term belongs to: PSMA PET.
Similar pages
not linked directly; found by shared links- IndicationNon-metastatic castration-resistant prostate cancer
Shares Metastatic hormone-sensitive prostate cancer, Biochemical recurrence of prostate cancer, PSMA PET, Prostate cancer.
- CollectionUroToday
Shares Renal cell carcinoma, Prostate cancer.
- TermBiochemical recurrence (BCR)
Shares PSMA-PET-guided metastasis-directed therapy as a curative strategy in oligorecurrent prostate cancer, PSMA PET, Prostate cancer.
- TrialCHAARTED (E3805)
Shares Metastatic hormone-sensitive prostate cancer, Prostate cancer.
- TrialA Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metasta
Shares Renal cell carcinoma, Prostate cancer.
- TrialPOP-RT
Shares PSMA PET, Prostate cancer.
- InstitutionRadboudumc Centre for Oncology
Shares PSMA PET, Prostate cancer.
- TrialBiodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
Shares Biochemical recurrence of prostate cancer, Prostate cancer.